42
Participants
Start Date
February 15, 2023
Primary Completion Date
March 15, 2025
Study Completion Date
December 15, 2025
Zanubrutinib, Bendamustine and Rituximab
Zanubrutinib, 160mg orally, twice a day; Bendamustine 70 mg/m2 on days 1 and 2 of each cycle; Rituximab (375 mg/m2 intravenously on day 0 of each cycle. ZBR was administered every 4 weeks for a total of 6 cycles, followed by maintenance therapy with zanubrutinib monotherapy for another 6 months.
RECRUITING
Institute of Hematology & Blood Diseases Hospital, Tianjin
Institute of Hematology & Blood Diseases Hospital, China
OTHER